Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed.
Ampersand Biomedicines launched out of Flagship Pioneering in March 2023. The company hopes the addition of AbCheck’s discovery platform will enable cost-effective and strategic acceleration of its own Address, Navigate, Determine (AND) platform.
Jason Gardner, CEO of Ampersand Biomedicines and Flagship Pioneering CEO-Partner, said: “I look forward to seamlessly integrating AbCheck’s broad antibody discovery capabilities and experienced team as one organisation and together building a pipeline of drug candidates that have efficacy, safety, and tolerability for Ampersand and in partnership with companies in the Flagship ecosystem.”
Over the last 15 years, AbCheck has been involved in more than 45 partnerships with biopharma companies and produced multiple clinical candidates.
Volker Lang, Managing Director of AbCheck, added: “We’re thrilled to join Ampersand and further our potential to discover and optimise novel antibodies against challenging disease targets through AND-body medicines.”